Sanofi (SAN.PA): analysis in plain words
Is Sanofi cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Sanofi (SAN.PA) is listed on Euronext Paris and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Sanofi according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Sanofi (SAN.PA) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | €84.10 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 24.3x | Price over earnings per share |
| Revenue growth | +15.7% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 8.2% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.0x | Years of operating profit to repay debt |
| Dividend yield | 5.09% | Annual dividend over price |
| Market cap | €100.8 billion | What the stock market values it at |
The Sanofi figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any SAN.PA figure that is not available shows as N/A: we do not estimate it.
How Sanofi makes money
Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. It sells to hospitals, pharmacies and health systems, with the US and Europe as its main markets.
Over the last 12 months, Sanofi brought in revenue of €51.0 billion. For every 100 it sells, Sanofi keeps 73.7 after the direct cost of what it sells (gross margin) and 30.9 after all operating costs (operating margin). With 74,846 full-time employees, that is about €681,000 of revenue per employee.
Sanofi against its sector
To know whether a Sanofi figure is high or low you have to put it next to similar companies. This table compares Sanofi with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Sanofi | healthcare and pharma median |
|---|---|---|
| P/E | 24.3x | 31.3x (30) |
| Revenue growth | +15.7% | +8.3% (33) |
| Net margin | 8.2% | 14.9% (33) |
| Dividend yield | 5.09% | 1.52% (33) |
| Net debt / EBITDA | 1.0x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Sanofi trades on a lower P/E, grows faster and earns a thinner margin. By size, Sanofi ranks number 1 of 5 healthcare and pharma companies quoted in EUR on Fintols.
The bull case for Sanofi
These are the strengths in the Sanofi figures as of November 4, 2026:
- Analysts expect Sanofi earnings to rise: its P/E on the next 12 months of estimated earnings is 9.0x, below the current 24.3x.
- Sanofi is selling more than a year ago: +15.7% in its latest quarter (the typical healthcare and pharma company grew +8.3%).
- Sanofi generates real cash: €8.1 billion of free cash flow over 12 months, 8.0% of its stock market value.
The main risk for Sanofi
Sanofi pays out more in dividends than it earns (a 119% payout ratio): its 5.09% yield only holds up if profit recovers.
And, like the rest of healthcare and pharma, Sanofi is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Sanofi
Is it a good time to buy Sanofi stock?
Fintols does not tell you whether to buy or sell Sanofi, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Sanofi stock trades at €84.10, 7% below its 52-week high (€90.79) and 21% above its low (€69.75). Its P/E is 24.3x against a healthcare and pharma median of 31.3x, and 9.0x on the earnings analysts expect over the next 12 months. With Sanofi, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Sanofi pay a dividend?
Yes. As of November 4, 2026, Sanofi pays €4.12 per share a year, which at today's price is a yield of 5.09%. It uses 119% of its profit to pay it, more than it earns, which cannot last forever. Its average dividend yield over the last five years is 4.02%. The healthcare and pharma median on Fintols is 1.52%.
Is Sanofi stock expensive?
It depends on what you compare it with. On P/E, Sanofi trades at 24.3x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). Including its debt, Sanofi is valued at 8.0x its EBITDA (EV/EBITDA). A high P/E alone does not make Sanofi expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Sanofi's competitors?
On Fintols we compare Sanofi with Bayer, argenx and Grifols, which are also in healthcare and pharma. As of November 4, 2026, Bayer is worth €53.3 billion; argenx is worth €51.3 billion and trades on a P/E of 32.8; Grifols is worth €7.6 billion and trades on a P/E of 15.8. Each has a side-by-side comparison with Sanofi below.
Sanofi competitors
- Bayer (BAYN.DE) analysis · Sanofi vs Bayer comparison
- argenx (ARGX.BR) analysis · Sanofi vs argenx comparison
- Grifols (GRF) analysis · Sanofi vs Grifols comparison
To understand Sanofi better
- DCF and WACC Explained: A Practical Valuation Guide
- Dividend Growth Investing: FCF Payout Ratio and Compounding
More companies like Sanofi: healthcare and pharma stocks and Euro Stoxx 50 companies. Open the full SAN.PA analysis with its valuation and scenarios. Educational content about Sanofi, not investment advice.